Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 16/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | BCR | P11274 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23566908 | 0.88 | SRC (0.39) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL30445323 | 0.88 | SRC (0.39) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL31435335 | 0.85 | KDM4E (0.44) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL2527205 | 0.82 | SRC (0.43) | SRCEGFRERBB2KDM4E | |
| SCHEMBL20918338 | 0.81 | DHFR (0.36) | SRCKDM4EALDH1A1 | |
| SCHEMBL20168442 | 0.81 | XDH (0.43) | SRC | |
| SCHEMBL19565811 | 0.79 | AR (0.44) | SRCEGFRERBB2KDM4EUSP2 | |
| SCHEMBL7875292 | 0.78 | MAP2K1 (0.44) | SRCEGFRERBB2KDM4EUSP2 | |
| SCHEMBL20168375 | 0.78 | EGFR (0.44) | SRCEGFRERBB2KDM4EUSP2 | |
| SCHEMBL16668884 | 0.78 | KDM4E (0.49) | SRCEGFRERBB2KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253015-B2 | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA TM2, INC. (US) | 2019-04-09 | — | — | US | claimed |
| US-20180327382-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-11-15 | — | — | US | claimed |
| US-20260027096-A1 | PHD INHIBITORS | UNIV OXFORD INNOVATION LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| EP-4655294-A1 | PYRAZOLE DERIVSTIVES AS PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | disclosed |
| EP-4655288-A1 | PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | disclosed |
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024157014-A1 | PYRAZOLE DERIVSTIVES AS PHD INHIBITORS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024157019-A1 | PHD INHIBITORS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-08-02 | — | — | WO | disclosed |
| EP-3929194-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240101535-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| CN-110139862-B | Substituted bicyclic heterocyclic derivatives useful as ROMK channel inhibitors | 百时美施贵宝公司 | 2024-01-16 | — | — | CN | disclosed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2010129379-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| EP-2187893-A2 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | Anacor Pharmaceuticals, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009111676-A2 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111676-A2 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | SRC 1665/4885EGFR 3338/4885ERBB2 2066/4885 |
| US-20260027096-A1 | PHD INHIBITORS | HIF1AN, HIF1A, EGLN1 | SRC 1600/4885EGFR 1949/4885ERBB2 1947/4885 |
| US-20240101535-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | WDR5, WDR1, WDR77 | SRC 3516/4885EGFR 4878/4885ERBB2 4849/4885 |
| US-10253015-B2 | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | IDH1, IDH3A, IDH3B | SRC 2461/4885EGFR 970/4885ERBB2 830/4885 |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | SRC 3411/4885EGFR 4570/4885ERBB2 2809/4885 |
| US-20180327382-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | SRC 2461/4885EGFR 970/4885ERBB2 830/4885 |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | SRC 4105/4885EGFR 3070/4885ERBB2 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.